These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 38182487)
21. Association analysis of Wnt pathway genes on prostate-specific antigen recurrence after radical prostatectomy. Huang SP; Ting WC; Chen LM; Huang LC; Liu CC; Chen CW; Hsieh CJ; Yang WH; Chang TY; Lee HZ; Bao BY Ann Surg Oncol; 2010 Jan; 17(1):312-22. PubMed ID: 19777185 [TBL] [Abstract][Full Text] [Related]
22. A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC. Schell MJ; Yang M; Teer JK; Lo FY; Madan A; Coppola D; Monteiro AN; Nebozhyn MV; Yue B; Loboda A; Bien-Willner GA; Greenawalt DM; Yeatman TJ Nat Commun; 2016 Jun; 7():11743. PubMed ID: 27302369 [TBL] [Abstract][Full Text] [Related]
23. Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer. Annala M; Struss WJ; Warner EW; Beja K; Vandekerkhove G; Wong A; Khalaf D; Seppälä IL; So A; Lo G; Aggarwal R; Small EJ; Nykter M; Gleave ME; Chi KN; Wyatt AW Eur Urol; 2017 Jul; 72(1):34-42. PubMed ID: 28259476 [TBL] [Abstract][Full Text] [Related]
24. Recurrent Mutations in APC and CTNNB1 and Activated Wnt/β-catenin Signaling in Intraductal Papillary Neoplasms of the Bile Duct: A Whole Exome Sequencing Study. Fujikura K; Akita M; Ajiki T; Fukumoto T; Itoh T; Zen Y Am J Surg Pathol; 2018 Dec; 42(12):1674-1685. PubMed ID: 30212390 [TBL] [Abstract][Full Text] [Related]
25. Mutations in APC, CTNNB1 and K-ras genes and expression of hMLH1 in sporadic colorectal carcinomas from the Netherlands Cohort Study. Lüchtenborg M; Weijenberg MP; Wark PA; Saritas AM; Roemen GM; van Muijen GN; de Bruïne AP; van den Brandt PA; de Goeij AF BMC Cancer; 2005 Dec; 5():160. PubMed ID: 16356174 [TBL] [Abstract][Full Text] [Related]
26. Comparative analysis of primary tumour and matched metastases in colorectal cancer patients: evaluation of concordance between genomic and transcriptional profiles. Vignot S; Lefebvre C; Frampton GM; Meurice G; Yelensky R; Palmer G; Capron F; Lazar V; Hannoun L; Miller VA; André F; Stephens PJ; Soria JC; Spano JP Eur J Cancer; 2015 May; 51(7):791-9. PubMed ID: 25797355 [TBL] [Abstract][Full Text] [Related]
27. Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer. Nientiedt C; Budczies J; Endris V; Kirchner M; Schwab C; Jurcic C; Behnisch R; Hoveida S; Lantwin P; Kaczorowski A; Geisler C; Dieffenbacher S; Falkenbach F; Franke D; Görtz M; Heller M; Himmelsbach R; Pecqueux C; Rath M; Reimold P; Schütz V; Simunovic I; Walter E; Hofer L; Gasch C; Schönberg G; Pursche L; Hatiboglu G; Nyarangi-Dix J; Sültmann H; Zschäbitz S; Koerber SA; Jäger D; Debus J; Duensing A; Schirmacher P; Hohenfellner M; Stenzinger A; Duensing S Urol Oncol; 2022 Jan; 40(1):8.e11-8.e18. PubMed ID: 34325986 [TBL] [Abstract][Full Text] [Related]
28. TP53 alterations of hormone-naïve prostate cancer in the Chinese population. Liu Z; Guo H; Zhu Y; Xia Y; Cui J; Shi K; Fan Y; Shi B; Chen S Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):482-491. PubMed ID: 33214693 [TBL] [Abstract][Full Text] [Related]
29. Molecular genetic analysis of 103 sporadic colorectal tumours in Czech patients. Vasovcak P; Pavlikova K; Sedlacek Z; Skapa P; Kouda M; Hoch J; Krepelova A PLoS One; 2011; 6(8):e24114. PubMed ID: 21901162 [TBL] [Abstract][Full Text] [Related]
30. Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer. Isaacsson Velho P; Fu W; Wang H; Mirkheshti N; Qazi F; Lima FAS; Shaukat F; Carducci MA; Denmeade SR; Paller CJ; Markowski MC; Marshall CH; Eisenberger MA; Antonarakis ES Eur Urol; 2020 Jan; 77(1):14-21. PubMed ID: 31176623 [TBL] [Abstract][Full Text] [Related]
31. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. Castro E; Goh C; Olmos D; Saunders E; Leongamornlert D; Tymrakiewicz M; Mahmud N; Dadaev T; Govindasami K; Guy M; Sawyer E; Wilkinson R; Ardern-Jones A; Ellis S; Frost D; Peock S; Evans DG; Tischkowitz M; Cole T; Davidson R; Eccles D; Brewer C; Douglas F; Porteous ME; Donaldson A; Dorkins H; Izatt L; Cook J; Hodgson S; Kennedy MJ; Side LE; Eason J; Murray A; Antoniou AC; Easton DF; Kote-Jarai Z; Eeles R J Clin Oncol; 2013 May; 31(14):1748-57. PubMed ID: 23569316 [TBL] [Abstract][Full Text] [Related]
32. Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer. Sonpavde G; Agarwal N; Pond GR; Nagy RJ; Nussenzveig RH; Hahn AW; Sartor O; Gourdin TS; Nandagopal L; Ledet EM; Naik G; Armstrong AJ; Wang J; Bilen MA; Gupta S; Grivas P; Pal SK; Lanman RB; Talasaz A; Lilly MB Cancer; 2019 May; 125(9):1459-1469. PubMed ID: 30620391 [TBL] [Abstract][Full Text] [Related]
33. APC and CTNNB1 mutations in a large series of sporadic colorectal carcinomas stratified by the microsatellite instability status. Løvig T; Meling GI; Diep CB; Thorstensen L; Norheim Andersen S; Lothe RA; Rognum TO Scand J Gastroenterol; 2002 Oct; 37(10):1184-93. PubMed ID: 12408524 [TBL] [Abstract][Full Text] [Related]
34. Clinicopathologic characteristics of FBXW7-mutated colorectal adenocarcinoma and association with aberrant beta-catenin localization. Escobar D; Bushara O; Sun L; Liao J; Yang GY Hum Pathol; 2022 Jan; 119():51-58. PubMed ID: 34717891 [TBL] [Abstract][Full Text] [Related]
35. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820 [TBL] [Abstract][Full Text] [Related]
36. Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations. Antonarakis ES; Shaukat F; Isaacsson Velho P; Kaur H; Shenderov E; Pardoll DM; Lotan TL Eur Urol; 2019 Mar; 75(3):378-382. PubMed ID: 30337059 [TBL] [Abstract][Full Text] [Related]
37. Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). James ND; Spears MR; Clarke NW; Dearnaley DP; De Bono JS; Gale J; Hetherington J; Hoskin PJ; Jones RJ; Laing R; Lester JF; McLaren D; Parker CC; Parmar MKB; Ritchie AWS; Russell JM; Strebel RT; Thalmann GN; Mason MD; Sydes MR Eur Urol; 2015 Jun; 67(6):1028-1038. PubMed ID: 25301760 [TBL] [Abstract][Full Text] [Related]
38. ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma. Laforest A; Aparicio T; Zaanan A; Silva FP; Didelot A; Desbeaux A; Le Corre D; Benhaim L; Pallier K; Aust D; Pistorius S; Blons H; Svrcek M; Laurent-Puig P Eur J Cancer; 2014 Jul; 50(10):1740-1746. PubMed ID: 24797764 [TBL] [Abstract][Full Text] [Related]
39. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma. Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368 [TBL] [Abstract][Full Text] [Related]
40. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer. Manzano RG; Catalan-Latorre A; Brugarolas A BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]